États-Unis · Bourse & Finance · Morningstar

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

Publié par Morningstar · États-Unis il y a 12 h

ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

À lire aussi

Anthropic can’t reliably control its AI agents. It’s cutting off its internal evals from the live internet instead

An NYU professor says OpenAI's mass release of math papers wiped out early-career researchers' projects

Trump turns to Russia in bid to lower diesel prices, but analysts see minimal impact

Trump's diesel agreement with Putin accused of contradicting Russia sanctions law

Big Controversy Upends a Contest About Microscopic Videos

Why Record Crude Output Can’t Solve America’s Diesel Crisis

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

Partager

À lire aussi

Anthropic can’t reliably control its AI agents. It’s cutting off its internal evals from the live internet instead

An NYU professor says OpenAI's mass release of math papers wiped out early-career researchers' projects

Trump turns to Russia in bid to lower diesel prices, but analysts see minimal impact

Trump's diesel agreement with Putin accused of contradicting Russia sanctions law

Big Controversy Upends a Contest About Microscopic Videos

Why Record Crude Output Can’t Solve America’s Diesel Crisis